Novavax (NVAX) Misses Q2 EPS by $1.12

Novavax (NASDAQ: NVAX) reported Q2 EPS of ($4.75), $1.12 worse than the analyst estimate of ($3.63). Revenue for the quarter came in at $298 million versus the consensus estimate of $387.87 million.

For earnings history and earnings-related data on Novavax (NVAX) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Investing.com’s stocks of the week
• Ubiquiti (UI) Tops Q4 EPS by 25c, Beats on Revenue